The Insider – Meet the Fund Manager – Luke Winchester

The Insider

Meet the Fund Manager

Luke Winchester

Founder and Portfolio Manager | Merewether Capital

The Insider sessions are a great way to hear directly from leading fund managers. They share their approach to investing, favourite companies and their market view for the year ahead.**

Favourite Stocks

Hear about this fintech software company, its tie-up with the Federal Government, and how despite being affected by lockdowns, Merewether believes it is poised to perform well over the next 2-3 years.

October 8th, 2021

Learn about how this healthcare solutions provider grew its revenue by 25% despite COVID limitations in FY21 and how it’s best-in-class product is set to disrupt the market.

October 8th, 2021

Learn how this healthcare solutions provider grew its revenue by 25% despite COVID limitations in FY21 and how its best-in-class product is set to disrupt the market.

October 8th, 2021

Like these investment ideas? Join our next session to discover more like this by clicking here

Insights

Luke expresses his views on inflation and how government institutions are reacting, cashed-up consumers, COVID-beneficiaries and what the reopening trade means for stocks.

October 8th, 2021

Luke outlines the opportunities and risks for stock in the reopening trade, including healthcare, mining, enterprise software, Fintech, travel and more.

October 8th, 2021

Luke Winchester joins us to talk about Merewether’s three favourite stocks, how it identifies high-performing stocks, how investors can gain an edge by looking beyond market trends, and more.

October 8th, 2021

Close

Register your details



By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets are the advisors assisting with the management of this offer and may receive fees depending on whether an offer is taken up by investors.

Meet the Fund Manager

Upcoming Session

Matt McNamara Board Director & CIOHorizon 3 Biotech

Meet the Manager

Get access to some of Australia’s leading fund managers who share their 3 favourite stocks, investment approach and insights on the market.

Each session includes:

  • 3 favourite stock opportunities
  • Market views for the year ahead
  • Investment strategy and approaches

This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.

Book into the next session

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.

Matt McNamara

Board Director & CIO
Horizon 3 Biotech

Horizon 3 Biotech, is a biotech venture capital company seeking to capitalise on opportunities presented by emerging therapeutic and medical device companies, and the low level of investment competition in the segment. The company manages the Horizon 3 Biotech Fund, a wholesale unit trust targeting $100 million in funding and a gross return of 20% per annum using an approach that hits key inflection points faster while limiting downside and increasing the upside. Matt McNamara has more than 30 years in healthcare and medical sciences and more than 20 years’ experience as a venture capitalist. His business acumen and strong background in the life sciences sector make him one of the industry’s most credible investment voices.

Past Sessions

Robert Calnon OC Funds Management

Hear about OC Funds Management, whose microcap fund was recently crowned Australia’s best-performing microcap fund by Morningstar (total return over five years). Robert Calnon, one of OC’s three highly experienced portfolio managers, shares his smallcap investing insights with us.

Matt McNamara Horizon 3 Biotech

Matt is a specialist in human healthcare technology and is passionate about investing in the commercialisation of this industry. He has spent more than 30 years in the healthcare and medical sciences sector and has more than 20 years’ experience as a venture capitalist. His business acumen and strong background in the life sciences sector make him one of the industry’s most credible investment voices.

David Keelan & Alexandra Clarke Ellerston Capital

Alexandra has worked in the finance market for 11 years and has extensive market IPO and pre-IPO experience. She provides in-depth research and analysis of stocks that range from micro to large caps covering the Industrial sector. David is a specialist investment manager with a distinctive approach to portfolio construction and investment selection.

** Reach does not assume responsibility for the accuracy or completeness of any information provided, and the views expressed are not reflective of Reach Markets position. Any advice contained within this presentation is general advice and does not consider your personal circumstance, you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.

Reach Markets

Reach Markets Pty Ltd - ABN 36 145 312 232

Is a Corporate Authorised Representative (CAR No:431191) of:

Reach Financial Group - ABN 17 090 611 680 AFSL Number 333297

Level 8, 525 Flinders Street, Melbourne Victoria

Level 7, 440 Collins Street, Melbourne 3000, Australia

Suite 803, Level 8, 14 Martin Place, Sydney 2000, Australia

T: 1300 80 57 95    

E: admin@reachmarkets.com.au

Neori theme, designed by litMotion Templates

Contact Luke Winchester Directly